Executive Board


Chief Executive Officer

20+ years of experience in management of Biopharmaceutical companies focused product development from bench to Phase III clinical trial. Dr Godfrin was co-Founder, former CEO and CSO of ERYTECH Pharma (EPA/NASDAQ: ERYP) and former CEO of Hemoxymed Europe. In addition to his entrepreurship, Dr Godfrin is an expert in pre-clinical and clinical product development strategy and has been consultant for several biopharmaceutical companies. He is the inventor of more than 15 patents families and several scientific publications. Dr Godfrin holds a Ph.D. degree in Health & Life Sciences (University of Nantes, France), an Engineer degree in Biomedical Sciences (University of Compiègne, France) and a Master degree in Pharmaceutical Drug Development (University of Lyon, France).

Supervisory Board

The supervisory board is non-executive, advise and control the executive board of the company.


President of the Supervisory Board

Foucauld de Tinguy du Pouet (HEC), founded a bank specialized in financial enginnering and in  bond and share arbitrage. He later was executive director of the largest independent French financial analysis company.

Pierre-Olivier GOINEAU


+20 years of experience in Business Development, especially in Biotech/Biopharma area. Mr Goineau was co-Founder and former CEO and COO of Erytech Pharma (EPA/NASDAQ: ERYP), former President of the association France Biotech, and is currently member of several supervisory boards, Pierre-Olivier Goineau is currently CEO of StromaCare.


Independant member

20+ years of experience in the pharmaceutical industry. First as Global discovery portfolio manager at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management. He established Biopolo Ticino before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he was VP and Director Corporate Licensing.

Gilles Avenard, M.D.

Independant Member

Current board member and advisor for several biotech companies, Gilles Avenard is CEO of Acticor Biotech. He was COO Medical Doctor and was the co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. He was notably involved in the development of several innovative medicines through to  their official registration on both European and North-American territories. Before that, he worked as Project Director for Hoechst Marion Roussel (Sanofi) and was Medical Director of Bio-Transfusion (LFB).

François MICELI


Representative of UI Investissement

+25 years of experience as entrepreneur and in risk capital investment in biotech companies. François is graduated in biological engineering from UPEC Paris XII, in corporate finance at INSEAD and was an auditor at the IHDEN.

He is Senior Partner in the Technological Team and Member of the Management Board of Sofimac Partners.

Isabelle De Baillenx


Representative of FaDièse

Isabelle de Baillenx founded FADiese funds.
She was a pioneer of this innovative model of funding, which consists in bringing together a team of venture-capital experts and seasoned entrepreneurs eager to share their knowledge and experience with the coming generations of entrepreneurs.
She graduated from HEC business school and has acquired a significant experience in venture-capital and M&A consulting.